| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/19/2022 | 66.61% | Cowen & Co. | $21 → $24 | Upgrades | Market Perform → Outperform |
| 10/07/2021 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 03/11/2020 | 108.26% | JP Morgan | $31 → $30 | Maintains | Overweight |
| 11/01/2019 | 35.37% | Cowen & Co. | → $19.5 | Initiates Coverage On | → Market Perform |
| 09/24/2019 | — | Jefferies | Initiates Coverage On | → Buy | |
| 03/19/2019 | — | Goldman Sachs | Reinstates | → Buy |
Takeda Pharmaceutical Questions & Answers
The latest price target for Takeda Pharmaceutical (NYSE: TAK) was reported by Cowen & Co. on July 19, 2022. The analyst firm set a price target for $24.00 expecting TAK to rise to within 12 months (a possible 66.61% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Takeda Pharmaceutical (NYSE: TAK) was provided by Cowen & Co., and Takeda Pharmaceutical upgraded their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Takeda Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Takeda Pharmaceutical was filed on July 19, 2022 so you should expect the next rating to be made available sometime around July 19, 2023.
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a upgraded with a price target of $21.00 to $24.00. The current price Takeda Pharmaceutical (TAK) is trading at is $14.41, which is out of the analyst's predicted range.